Janux Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
Janux Therapeutics, Inc. (JANX) reported Payments to Acquire Debt Securities, Available-for-sale of $257.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $144.84M, a 56.27% increase year-over-year.
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $112.75M, a 69.63% decline year-over-year.
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $123.28M, a 412.97% increase year-over-year.
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $117.97M, a 263.36% increase year-over-year.
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $705.22M, a 49.86% increase from fiscal 2024.
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $470.58M, a 48.29% increase from fiscal 2023.
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $317.34M, a 7.80% increase from fiscal 2022.
- Janux Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $294.39M, a 37.84% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $144.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $257.59M 10-Q · filed 2026-08-06 | $380.87M derived: sum of 3 quarters · filed 2026-08-06 | $498.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $112.75M 10-Q · filed 2026-05-07 | $236.03M derived: sum of 2 quarters · filed 2026-05-07 | $354.00M derived: sum of 3 quarters · filed 2026-05-07 | $446.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $123.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $241.25M derived: sum of 2 quarters · filed 2026-02-26 | $333.93M derived: sum of 3 quarters · filed 2026-08-06 | $705.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | $117.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $210.65M derived: sum of 2 quarters · filed 2026-08-06 | $581.95M 10-Q · filed 2025-11-06 | $605.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $92.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $463.98M 10-Q · filed 2026-08-06 | $488.01M derived: sum of 3 quarters · filed 2026-08-06 | $520.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $371.29M 10-Q · filed 2026-05-07 | $395.32M derived: sum of 2 quarters · filed 2026-05-07 | $427.79M derived: sum of 3 quarters · filed 2026-05-07 | $663.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $24.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $56.50M derived: sum of 2 quarters · filed 2026-02-26 | $292.04M derived: sum of 3 quarters · filed 2026-02-26 | $470.58M 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $268.01M derived: sum of 2 quarters · filed 2025-11-06 | $446.55M 10-Q · filed 2025-11-06 | $479.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $235.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $414.08M 10-Q · filed 2025-08-07 | $447.19M derived: sum of 3 quarters · filed 2026-02-26 | $583.17M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $178.54M 10-Q · filed 2025-05-08 | $211.65M derived: sum of 2 quarters · filed 2026-02-26 | $347.63M derived: sum of 3 quarters · filed 2026-02-26 | $424.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $33.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $169.09M derived: sum of 2 quarters · filed 2026-02-26 | $245.64M derived: sum of 3 quarters · filed 2026-02-26 | $317.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | $135.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $212.53M derived: sum of 2 quarters · filed 2024-11-06 | $284.23M 10-Q · filed 2024-11-06 | $370.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $76.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $148.25M 10-Q · filed 2024-08-07 | $234.30M derived: sum of 3 quarters · filed 2025-02-27 | $328.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $71.70M 10-Q · filed 2024-05-08 | $157.75M derived: sum of 2 quarters · filed 2025-02-27 | $252.22M derived: sum of 3 quarters · filed 2025-02-27 | $321.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $86.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $180.51M derived: sum of 2 quarters · filed 2025-02-27 | $249.33M derived: sum of 3 quarters · filed 2025-02-27 | $294.39M 10-K · filed 2025-02-27 |
| 2022-09-30 | $94.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $163.28M derived: sum of 2 quarters · filed 2023-11-07 | $208.34M 10-Q · filed 2023-11-07 | $311.84M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $68.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $113.87M 10-Q · filed 2023-08-08 | $217.38M derived: sum of 3 quarters · filed 2023-08-08 | $444.98M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $45.06M 10-Q · filed 2023-05-09 | $148.56M derived: sum of 2 quarters · filed 2023-05-09 | $376.17M derived: sum of 3 quarters · filed 2023-05-09 | $518.69M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $103.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $331.11M derived: sum of 2 quarters · filed 2023-03-10 | $473.63M derived: sum of 3 quarters · filed 2023-03-10 | $473.63M 10-K · filed 2023-03-10 |
| 2021-09-30 | $227.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $370.13M derived: sum of 2 quarters · filed 2022-11-10 | $370.13M 10-Q · filed 2022-11-10 | $370.13M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $142.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $142.52M 10-Q · filed 2022-08-09 | $142.52M derived: sum of 3 quarters · filed 2022-08-09 | $142.52M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | $0.00 derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |